Tri-VyLibra®

(norgestimate and ethinyl estradiol tablets, USP) 0.180 mg/0.035 mg, 0.215 mg/0.035 mg, and 0.250 mg/0.035 mg

Tri-VyLibra® is an AB-rated generic oral contraceptive.

Compares to

Ortho Tri-Cyclen®, Tri-Estarylla™, Tri-Linyah®, Tri-Mili™, Tri-Previfem®, Tri-Sprintec®, and TriNessa®

NDC#

50102-233-13

View Full Prescribing Information, Including Boxed Warning

Product Details

  • A progestin/estrogen combination oral contraceptive
  • Triphasic administration regimen
    • 7 white tablets with 0.18 mg/0.035 mg norgestimate/ethinyl estradiol
    • 7 light blue tablets with 0.215 mg/0.035 mg norgestimate/ethinyl estradiol
    • 7 dark blue tablets with 0.25 mg/0.035 mg norgestimate/ethinyl estradiol
    • 7 green placebo tablets to help ease administration
    • Combined in a 28-day tablet blister pack

Product Sheet

The Product Information Sheet features a summary of all relevant product information including Tri-VyLibra® (norgestimate and ethinyl estradiol tablets, USP) 0.180 mg/0.035 mg, 0.215 mg/0.035 mg, and 0.250 mg/0.035 mg product details, product description, NDC number, and product features.

Download Now

Product Features:

  • Tri-VyLibra is estrogen/progestin combined oral contraceptive (COC) indicated for use by women to prevent pregnancy and for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy, have achieved menarche, and who desire an oral contraceptive for birth control

The most common adverse reactions associated with Tri-VyLibra include headache/migraine, breast issues (including breast pain, enlargement, and discharge), vaginal infection, abdominal/gastrointestinal pain, mood disorders (including mood alteration and depression), genital discharge, changes in weight (including weight increased or decreased).

Use of COCs increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). The risk increases with age, particularly in women over 35 years of age who smoke.

View Full Prescribing Information, Including Boxed Warning

Distributor & Ordering Info

Tri-VyLibra®

NDC#: 50102-233-13

Package Size: A Carton Containing 3 Packages

Distributor Phone URL Order Number
AmerisourceBergen 1-610-727-7000 amerisourcebergen.com 10185559
ANDA 1-800-331-2632 (Ext. 74591) andanet.com 328026
ASD Healthcare 1-800-746-6273 asdhealthcare.com 51976
Cardinal Health 1-800-326-6457 cardinalhealth.com 5423181
McKesson 1-855-625-6285 mckesson.com 3562543
Morris & Dickson 1-888-376-7409 morrisdickson.com 225896
R & S Northeast 1-800-262-7770 rsnortheast.com 023313

Order Tri-VyLibra®
(norgestimate and ethinyl estradiol tablets, USP)

Order Now

Contact Your
Afaxys Pharma
Account Manager

Contact Now

View All
Afaxys Pharma
Products

View Now